UCB SA (OTCMKTS:UCBJF) Short Interest Up 20.8% in March

UCB SA (OTCMKTS:UCBJF) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 481,000 shares, a growth of 20.8% from the February 28th total of 398,200 shares. Approximately 0.3% of the company’s shares are short sold. Based on an average daily trading volume, of 3,100 shares, the short-interest ratio is presently 155.2 days.

UCB Stock Performance

UCBJF opened at $172.33 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The stock’s 50 day moving average price is $190.96 and its 200-day moving average price is $186.42. UCB has a one year low of $123.00 and a one year high of $209.66.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.